Drug Trial Radar · NCT05442047
A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis
Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Aug 2, 2022
Primary completion
Feb 17, 2025
Study completion May 13, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jul 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study will look at if this medicine can reduce the symptoms of a heart disease due to TTR amyloidosis, such as heart failure. Participants will either get NNC6019-0001 (apotential new medicine) or placebo (a medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting NNC6019-0001 is two times higher than getting placebo. NNC6019-0001 is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe yet. Participants will get an infusion of the study medicine 13 times, once every 4 weeks. The study will last for about 64 weeks after the first dose of medicine. Participants cannot participate in this study if they have a heart disease other than a heart disease due to TTR amyloidosis.
Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions
NNC6019-0001Drug
Participants will receive i.v infusionof NNC6019-0001.
Placebo (NNC6019-0001)Drug
Participants will receive i.v. infusion of placebo (NNC6019-0001).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in 6-minute walk test (6-MWT)Time frame: From baseline (week 0) to visit 15 (week 52)
- Change in N-terminal-pro brain natriuretic peptide (NT-proBNP)Time frame: From baseline (week 0) to visit 15 (week 52)
Locations
39 sites in 10 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
Cedars-Sinai Medical Center_Los Angeles
Beverly Hills, California
Stanford Hlth Cre-Boswell Clin
Stanford, California
Mayo Clinic Jacksonville
Jacksonville, Florida
NW Univ-Bluhm Cardiovasc Inst
Evanston, Illinois
Univ of MD Schl of Med
Baltimore, Maryland
University of Maryland School of Medicine
Baltimore, Maryland
Mayo Clinic Rochester
Rochester, Minnesota
Oregon Hlth Sci Univ-Portland
Portland, Oregon
University of Calgary_Cardiology
Calgary, Alberta, Canada
Ctr for Cardiovascular Innovation
Vancouver, British Columbia, Canada
II. interni klinika VFN - Kardiologie a angiologie
Prague, Czechia
Ap-Hp-Hopital Henri Mondor
Créteil, France
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil
Toulouse, France
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1
Toulouse Cedex 9 TSA 50032, France
UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie
Heidelberg, Germany
LMU Klinikum München Klinik und Poliklinik 1
München, Germany
Universitätsklinikum Münster - Klinik für Kardiologie I
Münster, Germany
Universitatsklinikum Wurzburg AöR
Würzburg, Germany
Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz
Würzburg, Germany
Fondazione Toscana Gabriele Monasterio - Dipartimento Cardiotoracico - UOC Cardiologia e Medicina Cardiovascolare
Pisa, Pi, Italy
Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo
Pavia, PV, Italy
Hospital of the University of Occupational and Environmental Health, Cardiology, Nephrology
Fukuoka, Japan
Hospital of the University of Occupational and Environmental Health
Fukuoka, Japan
Hiroshima University hospital, Cardiovascular Medicine
Hiroshima, Japan
Hiroshima University hospital_Cardiovascular Medicine
Hiroshima, Japan
Kumamoto University Hospital, Cardiovascular Medicine
Kumamoto-shi, Kumamoto, Japan
Shinshu University Hospital, Department of Neurology
Nagano, Japan
Nagasaki University Hospital, Cardiovascular Medicine
Nagasaki, Japan
Okayama University Hospital_Cardiovascular Medicine
Okayama-shi, Okayama, Japan
UMC Groningen afdeling Cardiologie
Groningen, Netherlands
UMC Groningen
Groningen, Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Hospital da Senhora da Oliveira - Guimarães
Guimarães, Portugal
ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães
Guimarães, Portugal
Unidade Local de Saude do Alto Ave, E.P.E.
Guimarães, Portugal
ULS De Tras-Os-Montes E Alto Douro E.P.E. - Unidade Hospitalar de Vila Real
Vila Real, Portugal
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.